Cite
Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk‐Enriched Rheumatoid Arthritis Patients.
MLA
Charles, Schoeman, Christina, et al. “Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk‐Enriched Rheumatoid Arthritis Patients.” Arthritis & Rheumatology, vol. 76, no. 8, Aug. 2024, pp. 1218–29. EBSCOhost, https://doi.org/10.1002/art.42846.
APA
Charles, S. C., Fleischmann, R., Mysler, E., Greenwald, M., Ytterberg, S. R., Koch, G. G., Bhatt, D. L., Wang, C., Mikuls, T. R., Chen, A., Connell, C. A., Woolcott, J. C., Menon, S., Chen, Y., Lee, K., & Szekanecz, Z. (2024). Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk‐Enriched Rheumatoid Arthritis Patients. Arthritis & Rheumatology, 76(8), 1218–1229. https://doi.org/10.1002/art.42846
Chicago
Charles, Schoeman, Christina, Roy Fleischmann, Eduardo Mysler, Maria Greenwald, Steven R. Ytterberg, Gary G. Koch, Deepak L. Bhatt, et al. 2024. “Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk‐Enriched Rheumatoid Arthritis Patients.” Arthritis & Rheumatology 76 (8): 1218–29. doi:10.1002/art.42846.